Madrigal Pharmaceuticals Reports Two-Year Rezdiffra Data Improving Liver Stiffness and Fibrosis Biomarkers
Madrigal Pharmaceuticals showed its Rezdiffra therapy cut liver stiffness and improved fibrosis biomarkers over two years in compensated MASH cirrhosis patients. These results suggest sustained reversal of chronic organ damage and strengthen the company’s clinical development outlook.
1. Two-Year Data Shows Rezdiffra Benefits
Madrigal Pharmaceuticals presented two-year follow-up results from its Rezdiffra program in compensated MASH cirrhosis patients, demonstrating significant improvements in liver stiffness and key fibrosis biomarkers. The multicenter study assessed the therapy’s durability, highlighting measurable reversal of chronic liver damage from baseline.
2. Clinical Significance for MASH Cirrhosis
Fibrosis and stiffness reduction in compensated MASH cirrhosis addresses a major unmet medical need, as no approved therapies currently alter disease progression. Sustained biomarker improvements over two years may support the use of noninvasive endpoints for regulatory filings and expedite patient access.
3. Outlook for Rezdiffra Development
Madrigal is poised to initiate discussions with regulators on trial design and potential accelerated approval pathways based on these two-year data. Future milestones include phase III enrollment targets, potential partnership negotiations for commercialization, and expanded manufacturing capabilities to meet market demand.